Effectiveness of first-line anticancer treatment may predict
treatment response in further lines in stage III/IV patients
with non-small cell lung cancer

J 2023

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

BRATOVÁ, Monika; Jana SKŘIČKOVÁ; Magda MATUSIKOVA; Karolina HRABCOVA; Libor HAVEL et. al.

Základní údaje

Originální název

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

Autoři

BRATOVÁ, Monika (203 Česká republika, domácí); Jana SKŘIČKOVÁ (203 Česká republika, domácí); Magda MATUSIKOVA (203 Česká republika); Karolina HRABCOVA (203 Česká republika); Libor HAVEL (203 Česká republika); Leona KOUBKOVA (203 Česká republika); Michal HRNCIARIK (203 Česká republika); Jana KREJCI (203 Česká republika); Ondrej FISCHER (203 Česká republika); Martin SVATON (203 Česká republika) a Kristián BRAT (703 Slovensko, garant, domácí)

Vydání

Journal of cancer research and clinical oncology, NEW YORK, Springer, 2023, 0171-5216

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.700

Kód RIV

RIV/00216224:14110/23:00132408

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00432-023-05431-5

UT WoS

001074760700001

EID Scopus

2-s2.0-85172661028

Klíčová slova anglicky

Non-small cell lung cancer; Anticancer treatment; Effectiveness; Overall survival; Progression-free survival

Štítky

14110215, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 2. 2024 12:57, Mgr. Tereza Miškechová

Anotace

V originále

PurposeThe aim of our study was to evaluate if therapeutic success in the first-line of anticancer treatments in patients with NSCLC may predict treatment success in the following lines.MethodsWe analyzed the data of patients with NSCLC stage III/IV from the TULUNG registry separately for chemotherapy, TKIs, ALK inhibitors, and immunotherapy in the first line during the years 2011-2019. ,,Succesful treatment " was defined as PFS >= 6 months, a ,,good responder " was a patient with >50% of ,,successful treatment " lines. Treatment responses were analyzed separately for each drug group. Descriptive statistics, Fisher exact test, Pearson Chi-Squared test, log-rank test, and univariate/multivariate logistic regression models were used.ResultsThe first-line TKI therapy was successful in 66.2%, while good responders accounted for 50.7% of the cohort and their rates were similar for all types of TKIs. First-line platinum-based chemotherapy was successful in 43.1% and 48.6% for combinations with pemetrexed and bevacizumab, respectively. Good responders accounted for 29.5% and 25.9%, respectively. In the group of ALK inhibitors, we observed treatment success in 52.3% of cases, while alectinib showed the highest effectiveness (up to 70%). Good responders constituted 50% of the group. In the first-line immunotherapy group, survival benefit was observed in 52.3%, and good responders constituted 52.3% of the cohort.ConclusionWe concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.

Citovat

BRATOVÁ, Monika; Jana SKŘIČKOVÁ; Magda MATUSIKOVA; Karolina HRABCOVA; Libor HAVEL; Leona KOUBKOVA; Michal HRNCIARIK; Jana KREJCI; Ondrej FISCHER; Martin SVATON a Kristián BRAT. Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer. Journal of cancer research and clinical oncology. NEW YORK: Springer, 2023, roč. 149, č. 19, s. 17123-17131. ISSN 0171-5216. Dostupné z: https://dx.doi.org/10.1007/s00432-023-05431-5.

@article{2345959,
   author = {Bratová, Monika and Skřičková, Jana and Matusikova, Magda and Hrabcova, Karolina and Havel, Libor and Koubkova, Leona and Hrnciarik, Michal and Krejci, Jana and Fischer, Ondrej and Svaton, Martin and Brat, Kristián},
   article_location = {NEW YORK},
   article_number = {19},
   doi = {http://dx.doi.org/10.1007/s00432-023-05431-5},
   keywords = {Non-small cell lung cancer; Anticancer treatment; Effectiveness; Overall survival; Progression-free survival},
   language = {eng},
   issn = {0171-5216},
   journal = {Journal of cancer research and clinical oncology},
   title = {Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer},
   url = {https://link.springer.com/article/10.1007/s00432-023-05431-5},
   volume = {149},
   year = {2023}
}

TY  - JOUR
ID  - 2345959
AU  - Bratová, Monika - Skřičková, Jana - Matusikova, Magda - Hrabcova, Karolina - Havel, Libor - Koubkova, Leona - Hrnciarik, Michal - Krejci, Jana - Fischer, Ondrej - Svaton, Martin - Brat, Kristián
PY  - 2023
TI  - Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer
JF  - Journal of cancer research and clinical oncology
VL  - 149
IS  - 19
SP  - 17123-17131
EP  - 17123-17131
PB  - Springer
SN  - 01715216
KW  - Non-small cell lung cancer
KW  - Anticancer treatment
KW  - Effectiveness
KW  - Overall survival
KW  - Progression-free survival
UR  - https://link.springer.com/article/10.1007/s00432-023-05431-5
N2  - PurposeThe aim of our study was to evaluate if therapeutic success in the first-line of anticancer treatments in patients with NSCLC may predict treatment success in the following lines.MethodsWe analyzed the data of patients with NSCLC stage III/IV from the TULUNG registry separately for chemotherapy, TKIs, ALK inhibitors, and immunotherapy in the first line during the years 2011-2019. ,,Succesful treatment " was defined as PFS >= 6 months, a ,,good responder " was a patient with >50% of ,,successful treatment " lines. Treatment responses were analyzed separately for each drug group. Descriptive statistics, Fisher exact test, Pearson Chi-Squared test, log-rank test, and univariate/multivariate logistic regression models were used.ResultsThe first-line TKI therapy was successful in 66.2%, while good responders accounted for 50.7% of the cohort and their rates were similar for all types of TKIs. First-line platinum-based chemotherapy was successful in 43.1% and 48.6% for combinations with pemetrexed and bevacizumab, respectively. Good responders accounted for 29.5% and 25.9%, respectively. In the group of ALK inhibitors, we observed treatment success in 52.3% of cases, while alectinib showed the highest effectiveness (up to 70%). Good responders constituted 50% of the group. In the first-line immunotherapy group, survival benefit was observed in 52.3%, and good responders constituted 52.3% of the cohort.ConclusionWe concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.
ER  -

BRATOVÁ, Monika; Jana SKŘIČKOVÁ; Magda MATUSIKOVA; Karolina HRABCOVA; Libor HAVEL; Leona KOUBKOVA; Michal HRNCIARIK; Jana KREJCI; Ondrej FISCHER; Martin SVATON a Kristián BRAT. Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer. \textit{Journal of cancer research and clinical oncology}. NEW YORK: Springer, 2023, roč.~149, č.~19, s.~17123-17131. ISSN~0171-5216. Dostupné z: https://dx.doi.org/10.1007/s00432-023-05431-5.

Přehled o publikaci